Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis

Citation
A. Scarpa et al., Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis, GUT, 46(6), 2000, pp. 842-848
Citations number
29
Categorie Soggetti
Gastroenerology and Hepatology","da verificare
Journal title
GUT
ISSN journal
00175749 → ACNP
Volume
46
Issue
6
Year of publication
2000
Pages
842 - 848
Database
ISI
SICI code
0017-5749(200006)46:6<842:COTAOV>2.0.ZU;2-7
Abstract
Background-Cancer of the ampulla of Vater kills 60% of affected patients. L ocal spread of the tumour (T stage) is the only reliable prognostic factor. Nevertheless, any cancer stage includes long term survivors and patients d ying from the disease. The molecular anomalies involved in this process hav e the potential to serve as additional prognostic markers. Aim-To evaluate if allelic losses (LOH) of chromosomes 17p and 18q may be o f prognostic value in multivariate survival analysis. Methods-We examined 53 ampullary cancers for chromosome 17p and 18q LOH usi ng microsatellite markers and DNA from paraffin embedded tumours. All patie nts were treated by surgery alone (pancreaticoduodenectomy). Multivariate s urvival analysis included age, sex, tumour size, macroscopic appearance, gr ade of differentiation, T stage, lymph node metastasis, and chromosome 17p and 18q status. Results-Chromosome 17p and 18q LOH were detected in 28 (53%) and 18 (34%) c ancers, respectively. Multivariate survival analysis indicated chromosome 1 7p status as an independent prognostic factor together with T stage. The fi ve year survival for chromosome 17p retention and 17p loss was 80% and 7%, respectively. The risk of death from cancer within the five year follow up period for patients with cancers harbouring chromosome 17p LOH was 11 times higher than that of patients with cancers retaining chromosome 17p (p<0.00 01), regardless of the tumour stage at diagnosis. Conclusions-Chromosome 17p status is an independent prognostic factor among ampullary cancers at the same stage. The combined use of T stage and chrom osome 17p status may help in deciding whether ampullary cancer patients req uire additional therapy other than surgery alone.